CMV Infection Clinical Trial
Official title:
Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Viral infections are common complications after allo-HSCT. With wide use of HLA-mismatch,
unrelated and cord blood donors as alternative sources of hematopoietic stem cells, and
anti-thymocyte globulin (ATG) as the standard prophylaxis of graft versus host disease
(GVHD) in HLA-mismatch and unrelated donor transplantation, allo-HSCT recipients are at
increasing risk for viral infections.
Till now, CMV remains one of the most important viruses and causes of death in the
recipients of allo-HSCT. Approximately 75% of CMV-seropositive recipients develop CMV
reactivation, and 20-30% of these patients develop CMV disease without intervention.
Ganciclovir is the first-line treatment of CMV diseases. However, bone marrow suppression,
which is the main and common side effect, limits the utility of ganciclovir in allo-HSCT
recipients. Besides, ganciclovir and other antiviral agents resistance has been reported up
to 28%. Since it has been known that specific immune response to CMV is important to control
reactivation, CMV-specific CTL has been used in prophylaxis and treatment of CMV viremia in
several studies. However, the production of CTL requires time. Mesenchymal stem cells (MSC)
are a form of multipotent adult stem cells that can be isolated from bone marrow (BM),
adipose tissue, and cord blood. In vivo experiment showed that MSCs have antimicrobial
activity.
In this trial, we will use MSCs in the recipients with refractory CMV infections.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02241031 -
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02240992 -
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
|
Phase 2/Phase 3 | |
| Completed |
NCT02483325 -
Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
|
Phase 2 | |
| Recruiting |
NCT05041933 -
Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting
|
||
| Completed |
NCT00675038 -
Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload
|
N/A | |
| Active, not recruiting |
NCT03745287 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05505760 -
Testing Content Delivery Models for MomConnect
|
N/A | |
| Recruiting |
NCT01160952 -
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT00884364 -
Exercise During Chemotherapy for Patients With Hematological Malignancies
|
Phase 3 | |
| Completed |
NCT00892502 -
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
|
N/A | |
| Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
| Recruiting |
NCT05329649 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
|
Phase 3 | |
| Not yet recruiting |
NCT06281496 -
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT02661035 -
Allo HSCT Using RIC for Hematological Diseases
|
Phase 2 | |
| Enrolling by invitation |
NCT06277479 -
Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
|
||
| Completed |
NCT00956358 -
Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT01344681 -
Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
|
Phase 2 | |
| Recruiting |
NCT02083718 -
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
|
Phase 2 | |
| Recruiting |
NCT01763086 -
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT01763099 -
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure
|
Phase 2 |